Multi-arm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling Meeting Abstract
| Authors: | Garrido, P.; Felip, E.; Delord, J. P.; Paz-Ares, L.; Barlesi, F.; Arkenau, H.; Lara, P.; Paik, P. K.; Morgensztern, D.; Gadgeel, S.; Reckamp, K.; Bertino, E.; Orlov, S.; Levchenko, E.; Delgado, I.; Trigo, J. M.; Viteri, S.; Vansteenkiste, J. F.; Kindler, H.; Lassen, U. N. |
| Abstract Title: | Multi-arm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling |
| Meeting Title: | 39th ESMO Congress (ESMO 2014) |
| Journal Title: | Annals of Oncology |
| Volume: | 25 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2014 Sep 26-30 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2014-09-01 |
| Start Page: | iv425 |
| Language: | English |
| ACCESSION: | WOS:000346901000360 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdu348.25 |
| Notes: | Meeting Abstract: 1220TiP -- Source: Wos |
